

CURRICULUM VITAE

Phillip A Reece PhD MRACI CChem

ABN 79 788 399 683



Biotechnology & Pharmaceutical Consultant

PO Box 371

Mont Albert VIC 3127

Australia

Mobile: +61407690401

Email: phillip.reece@gmail.com

Web: www.phillipreece.com.au

Honorary Senior Fellow

Department of Pharmacology

The University of Melbourne

Melbourne VIC 3010

Australia

Phone: +61383444209

Fax: +61383440241

Email: preece@unimelb.edu.au

Website: <http://www.findanexpert.unimelb.edu.au/researcher/person27905.html>

See also refereed international experts site, Intota: <http://www.intota.com/expert-consultant.asp?biolD=777929&perID=727493>

SUMMARY

- Phillip Reece is a consultant expert with over 30 years experience in the research and development of human pharmaceuticals
- Trained in organic chemistry at the University of Adelaide and medical chemistry at the Australian National University, Canberra
- Undertook clinical pharmacology research in antihypertensive and anticancer drugs at the Queen Elizabeth Hospital, an Adelaide University teaching hospital, for 12 years before joining Astra Pharmaceuticals, Sydney in 1987
- Appointed Associate Regional Director, Clinical Research, Parke-Davis, Sydney, Australia in 1988 and responsible for Phase I through Phase III clinical trials monitored trials to FDA standards in Australia, New Zealand, and SE Asia
- Appointed Director of Clinical Pharmacology, Parke Davis, Ann Arbor, MI, USA in 1990 and responsible for Phase I trials of CNS drugs
- Appointed Director of Research and Development in 1993 at Biota Holdings, one of Australia's leading biotechnology companies and founder of the influenza antiviral, zanamivir
- Since 2002 held several senior industry roles including CEO of Boron Molecular, a fine chemicals company, Chairman of Cryptopharma, an early stage biotechnology company developing new anti-inflammatory drugs, and non-executive Director of EnGeneIC, a privately held company developing a new vehicle for delivering anticancer drugs
- Acted as a consultant expert to lawyers engaged in one of Australia's largest commercial litigation cases. This involved communicating complex scientific issues to the legal team, assisting in the preparation of questions for expert witnesses, and preparing technical reports, chronologies and literature reviews for the case
- Consultant expert in the areas of pharmaceutical development, clinical trials, pharmacokinetics, pharmacodynamics and intellectual property matters to biotechnology companies, pharmaceutical companies and law firms
- Experience as an independent expert witness in areas of professional expertise
- 67 refereed scientific publications in the areas of human pharmacokinetics, clinical trials, respiratory antivirals particularly for influenza, anticancer drugs and antihypertensives; 3 book chapters on antihypertensives and an inventor on three published patents in the area of respiratory antivirals

EDUCATION

1973 –1975	PhD, John Curtin School, ANU, Canberra – Medical Chemistry
1972	BSc (Hons), University of Adelaide– 1st Class Honours – Organic Chemistry
1969 – 1971	BSc, University of Adelaide – Organic Chemistry & Biochemistry

CAREER**Current**

May 09 – present	Independent expert witness in areas of professional expertise
May 03 –present	Consultant to the biotechnology, pharmaceutical and legal industries
Dec 03 – present	Senior Fellow (Honorary), Department of Pharmacology, University of Melbourne, Melbourne

Previous

Feb 04 – Nov 08	Consultant Project Manager to Biota Holdings, Melbourne
Dec 03 – Apr 08	Non-executive Chairman, Cryptopharma Pty Ltd, Melbourne
Mar 02 – May 03	CEO and Managing Director, Boron Molecular Ltd, Melbourne
Dec 01 – Mar 02	General Manager, Australian Operations, Biota Holdings, Melbourne
May 01 – Mar 02	Non-executive Director, Biota Inc, Carlsbad, CA, USA
Dec 00 – Feb 09	Non-executive Director, EnGeneIC Pty Ltd, Sydney
July 94 –May 95	Acting CEO, Biota Holdings, Melbourne
Oct 93 – Dec 01	Director, Research and Development, Biota Holdings, Melbourne
Aug 90 – Sep 93	Director, Clinical Pharmacology, Parke Davis Ltd, Ann Arbor MI, USA
Sep 98 – Aug 90	Associate Regional Director, Clinical Research, Parke Davis, Sydney
Sep 87 – Sep 88	Clinical Trials Manager, Astra Pharmaceuticals, Sydney
Jan 86 – Sep 87	External Drug Evaluator for the Australian Department of Health, Canberra
Feb 83 – Sep 87	Chief Hospital Scientist, The Queen Elizabeth Hospital, Adelaide
Dec 75 – Feb 83	Principal Hospital Scientist, The Queen Elizabeth Hospital, Adelaide

KEY AWARDS

1983	Churchill Fellowship, Anticancer drugs, Mayo Clinic, USA
1985	International Cancer Research Technology Transfer, Institute of Cancer Research, Belmont, Sutton, Surrey, UK

PROFESSIONAL ASSOCIATIONS

Royal Australian Chemical Institute

Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists

DETAILS OF MOST RECENT POSITIONS**Independent Expert witness – May 2009 to present****Biota Holdings – Project Manager – Feb 04 to Aug 08**

- Acted as a consultant expert to lawyers engaged in one of Australia's largest commercial litigation cases
- Involved communicating complex scientific issues to the legal team, assisting in the preparation of questions for expert witnesses, and preparing technical reports, chronologies and literature reviews for the case

Cryptopharma – Chairman – Dec 03 to Apr 08

- Chaired Board meetings as an independent, non-executive Director
- Participated in Scientific Advisory Board meetings during the initial years of the Company
- Intellectual property rights have since been returned to the University of Melbourne

Boron Molecular - CEO & Managing Director - Mar 02 to May 03

- Overall responsibility for the management of the Company
- Stabilized the business & recruited management team
- Raised \$1.9M through a private placement
- Wrote new business plan for redirection of corporate strategy
- Prepared prospectus for a public offering (Boron Molecular is now a subsidiary of XCEED)

- Grew revenues in 1st three quarters of 2002/3 by >100% compared with same period in 2001/2
- Attained near breakeven
- Established systems and quality control procedures

Biota Holdings – Director R&D - Sep 93 to Feb 02

- Responsible for all research and development activities of the Company
- Initiated and completed development of the flu diagnostic, FLUOIA®, for international marketing
- Built R&D team as inaugural R&D Director
- Established laboratory facilities
- Managed R&D relationship with GSK on Relenza®
- Screened opportunities for Biota's US-based operations
- Diversified Biota's R&D portfolio

Parke-Davis (Ann Arbor, MI, USA) – Director, Clinical Pharmacology – Sep 90 to Sep 93

- Managed transition of new pharmaceuticals for CNS diseases from pre-clinical to Phase I and Phase IIA clinical studies
- Managed staff involved in Phase I and IIA CNS studies
- Prepared clinical pharmacology reports for IND and NDA applications
- Reviewed pre-clinical data for suitability for IND applications and Phase I studies in CNS
- Attended all research and team meetings in the CNS preclinical and clinical area

Parke-Davis (Sydney, Australia) – Associate Regional Director, Clinical Research, Sep 88 to Aug 90

- Responsible for Phase I through Phase III clinical trials conducted in centres in Australia, New Zealand, and SE Asia
- Reported directly to head office
- Monitored clinical trials to FDA standards for gabapentin, quinapril and an anticancer drug developed in Auckland, New Zealand.

REFEREED PUBLICATIONS AND BOOK CHAPTERS (Excludes Abstracts)

1. **Reece PA.** Treatment options for H5N1: Lessons learned from the H1N1 pandemic. *Postgrad Med* 122(5):134-141 (2010).
2. **Reece PA.** Zanamivir for the treatment of avian influenza (H5N1) infections in humans. *Expert Rev Clin Pharmacol* 3(1):25-29 (2010).
3. **Reece PA.** Neuraminidase inhibitor resistance in influenza viruses. *J Med Virol.* 2007 Aug 17;79 (10):1577-1586.
4. Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, **Reece PA.** In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. *Antimicrob Agents Chemother.* 2004 May;48(5):1766-72.
5. Macdonald SJ, Watson KG, Cameron R, Chalmers DK, Demaine DA, Fenton RJ, Gower D, Hamblin JN, Hamilton S, Hart GJ, Inglis GG, Jin B, Jones HT, McConnell DB, Mason AM, Nguyen V, Owens IJ, Parry N, **Reece PA,** Shanahan SE, Smith D, Wu WY, Tucker SP. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. *Antimicrob Agents Chemother.* 2004 Dec;48(12):4542-9.
6. McKimm-Breschkin JL, Colman PM, Jin B, Krippner GY, McDonald M, **Reece PA,** Tucker SP, Waddington L, Watson KG, Wu WY. Tethered neuraminidase inhibitors that bind an influenza virus: A first step towards a diagnostic method for influenza. *Angew Chem Int Ed Engl* 42(27):3118-3121 (2003)
7. Watson KG, Brown RN, Cameron R, Chalmers DK, Hamilton S, Jin B, Krippner GY, Luttick A, McConnell DB, **Reece PA,** Ryan J, Stanislawski P, Tucker SP, Wu WY, Barnard DL, Sidwell RW. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. *J Med Chem* 46(15):3181-3184 (2003)
8. Begg EJ, Robson RA, Gardiner SJ, Hudson LJ, **Reece PA,** Olson SC, Sedman AJ. Quinapril and its metabolite quinaprilat in human milk. *Br J Clin Pharmacol* 51(5):478-481 (2001)
9. Allen E, Tsanaclis LM, Wroe SJ, **Reece PA,** Sedman AJ. Gabapentin does not affect antipyrine clearance. *J Clin Pharmacol* 39:934-935 (1999)
10. Fogue ST, **Reece PA,** Sedman AJ, deVries TM. Inhibition of tacrine oral clearance by cimetidine. *Clin Pharmacol Ther* 59(4):444-449 (1996)
11. Sramek, JJ, Sedman AJ, **Reece PA,** Hourani J, Bockbrader H, Cutler NR. Safety and tolerability of CI-979 in patients with Alzheimer's disease. *Life Sciences* 57(5):503-510 (1995)
12. Bradwejn J, Koszycki D, Paradis M, **Reece P,** Hinton J, Sedman A. Effect of CI-988 on cholecystokinin tetra-peptide induced panic symptoms in healthy volunteers. *Biol Psychiatry* 38(11):742-746 (1995)
13. **Reece PA,** Garnett WR, Rock WL, Taylor JR, Underwood B, Sedman AJ, Rajagopalan R. Lack of effect of tacrine administration on the anticoagulant activity of warfarin. *J Clin Pharmacol* 35:526-528 (1995)

14. Blum RA; Comstock TJ; Sica DA; Schultz RW; Keller E; Reetze P; Bockbrader H; Tuerck D; Busch JA; **Reece PA**; et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. *Clin Pharmacol Ther* 56(2):154-159 (1994)
15. **Reece PA**, Sedman AJ, Rose S, Wright DS, Dawkins R. Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. *J Clin Pharmacol* 34(11):1126-1132 (1994)
16. Begg EJ, Robson RA, Ikram H, Richards AM, Bammert-Adams JA, Olson SC, Posvar EL, **Reece PA**, Sedman AJ. The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure. *Br J clin Pharmacol* 37:302-304 (1994)
17. Davis R, Raby C, Callahan MJ, Lipinski W, Schwarz R, Dudley D, Lauffer D, **Reece PA**, Jaen J, Teclé H. Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease. *Progress in Brain Research* 98:439-445 (1993)
18. Olver IN, **Reece PA**, Bishop JF, Morris RG, Hillcoat BL and Guentert TW. A Phase 1 Study of doxifluridine as a five-day stepped-dose continuous infusion. *Am J Clin Oncol* 13 (4):308-311 (1990)
19. **Reece PA**, Olver IN, Morris RG, Bishop JF, Guentert TW, Hill HS and Hillcoat BL. Pharmacokinetic study of doxifluridine given by five-day stepped-dose infusion. *Cancer Chemother Pharmacol* 25:274-278 (1990).
20. **Reece PA** and Zacest R. Hydralazine. In: FH Messerli (ed), *Cardiovascular Drug Therapy*, WB Saunders, New York, 1990, pp 834-848.
21. **Reece PA**, Stafford I, Davy M and Freeman S. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer. *Cancer Chemother Pharmacol* 24:256-260 (1989).
22. Bishop JF, Raghavan D, Olver IN, **Reece PA**, Morris RG and Friedlander ML. A phase I study of trimetrexate (NSC 352 122) administered by 5 day continuous infusion. *Cancer Chemother Pharmacol* 24:246-250 (1989).
23. Morris RG, Dale BM, Green RM, **Reece PA**, Kotasek D, Saccoia LC and Sage RE. Alteration in duxorubicin and duxorubicinol plasma concentrations with repeated courses to patients. *Therapeutic Drug Monitoring* 11:380-383 (1989).
24. **Reece PA**, Stafford I, Abbott RL, Anderson C, Denham J, Freeman S, Morris RG, Gill PG and Olweny CL. Two versus twenty-four infusion of cisplatin: pharmacokinetic considerations. *J Clin Oncol* 7:270-275 (1989).
25. **Reece PA**, Hill HS, Green R G, Morris RG, Dale BM, Kotasek D and Sage RE. Renal clearance and protein binding of melphalan in patients with cancer. *Cancer Chemother Pharmacol* 22:348-352 (1988).

26. Zacest R and **Reece PA**. Hydralazine. In: WH Birkenhager and JL Reid, Handbook of Hypertension Vol 5: Pharmacology of Antihypertensive Drugs, Elsevier, Amsterdam, 1988 pp 341-381 (Review).
27. Powis G, **Reece PA**, Ahmann DL and Ingle JN. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. *Cancer Chemother Pharmacol* 20:219-222 (1987).
28. **Reece PA**, Stafford I, Russell J, Khan M and Gill PG. A model for ultrafilterable platinum disposition in patients treated with cisplatin. *Cancer Chem Pharmacol* 20:26-32 (1987).
29. **Reece PA**, Bishop JF, Olver IN, Stafford I, Hillcoat BL and Morstyn G. Pharmacokinetics of carboplatin (CBDCA) in patients with small cell lung carcinoma. *Cancer Chemother Pharmacol* 19:326-330 (1987).
30. **Reece PA**, Morris RG, Bishop JF, Olver IN and Raghavan D. Pharmacokinetics of trimetrexate administered by five day continuous infusion to patients with advanced cancer. *Cancer Res* 47:2996-2999 (1987).
31. **Reece PA**, Stafford I, Davy M and Freeman S. Disposition of unchanged cisplatin in patients with ovarian cancer. *Clin Pharmacol Ther* 42:320-325 (1987).
32. **Reece PA**, Dale BM, Morris RG, Kotasek D, Gee D, Rogerson S and Sage RE. Effect of L-leucine on oral melphalan kinetics in patients. *Cancer Chemother Pharmacol* 20:256-258 (1987).
33. Imhoff DM, **Reece PA**, Dimitriadis E, Ward D and Bochner F. Direct measurement of salicylphenolic glucuronide in human urine. *Ther Drug Monit* 8:321-325 (1986).
34. **Reece PA**, Stafford I, Russell J and Gill PG. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin to patients. *J Clin Oncol* 4:1392-1398 (1986).
35. **Reece PA**, Stafford I, Russell J, Khan M and Gill PG. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin. Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. *J Clin Oncol* 5:304-309 (1986).
36. **Reece PA**, Kotasek D, Morris RG, Dale BM and Sage RE. The effect of food on oral melphalan absorption. *Cancer Chemother Pharmacol* 16:194-197 (1985).
37. **Reece PA**, Cozamanis I, Russell J and Gill PG. Nonlinear renal clearance of ultrafilterable platinum in patients treated with cisplatin. *Cancer Chemother Pharmacol* 15:295-299 (1985).
38. **Reece PA**, Disney AP, Stafford I and Shastry JCM. Prednisolone protein binding in renal transplant patients. *Brit J Clin Pharmacol* 20:159-162 (1985).
39. **Reece PA**, Cozamanis I and Zacest R. The synthesis, formulation and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone in two healthy volunteers. *J Pharm Sci* 74:193-196 (1985).

40. Zacest R and **Reece PA**. Hydralazine. In: WH Birkenhager and JL Reid, Handbook of Hypertension Vol 5: Pharmacology of Antihypertensive Drugs, Elsevier, Amsterdam, 1984 pp 312-349 (Review).
41. **Reece PA**, McCall JT, Powis G and Richardson RL. Sensitive high performance liquid chromatographic assay for platinum in plasma ultrafiltrate. *J Chromatogr* 306:417-423 (1984).
42. Morris RM and **Reece PA**. Sensitive gas liquid chromatographic-nitrogen detection assay for fenfluramine and nor-fenfluramine in human plasma. *J Chromatogr* 278:434-438 (1983).
43. Zacest R and **Reece PA**. Endralazine and sexual arousal. *Lancet*, May 28, 1221 (1983) (Letter).
44. **Reece PA**, Cozamanis I and Zacest R. Endralazine - A new hydralazine-like antihypertensive with high systemic bioavailability. *Eur J Clin Pharmacol* 25:553-556 (1983).
45. Jones T, **Reece PA** and Sansom L. Mexiletine removal in peritoneal dialysis. *Eur J Clin Pharmacol* 25:839-840 (1983) (Letter).
46. Zacest R and **Reece PA**. I.V. Hydralazine. *Med J Aust* June, 497-498 (1982).
47. **Reece PA**, Cozamanis I and Zacest R. Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine. *Eur J Clin Pharmacol* 23:523-527 (1982).
48. **Reece PA**, Cozamanis I and Zacest R. Pharmacokinetics of the vasodilators hydralazine and endralazine. In: LZ Benet and G Levy (eds), *Pharmacokinetics, A Modern View*, Plenum, New York, 1982.
49. **Reece PA**. Hydralazine and related compounds - chemistry, mode of action and metabolism. *Medicinal Research Reviews* 1:73-96 (1981) (Review).
50. **Reece PA**. The application of a fully automated high pressure liquid chromatography to multiple drug analyses. *Chromatography Review* 7:14-15 (1981).
51. Armarego WLF and **Reece PA**. Quinazolines, XXV. The synthesis of 2-(4-(2-furoyl)piperazin-1-yl)-8-chloro-6,7-dimethoxyquinazolin-4-ylamine hydrochloride (8-chloroprazosin hydrochloride). *Aust J Chem* 34:1561-1566 (1981).
52. **Reece PA**, Cozamanis I and Zacest R. A sensitive assay for endralazine and two of its metabolites in human plasma. *J Chromatogr* 225:151-160 (1981).
53. Lane MJ, **Reece PA** and Schapel GJ. Excessive frequency of phenytoin dosage. *Med J Aust* 1:191-192 (1981) (Letter).
54. **Reece PA**, Cozamanis I and Zacest R. Selective HPLC assays for hydralazine and its metabolites in plasma of man. *J Chromatogr* 181:427-440 (1980).
55. **Reece PA** and Stanley PE. High performance liquid chromatographic assay for tocainide in human plasma : comparison with gas-liquid chromatography. *J Chromatogr* 183:109-114 (1980).

56. **Reece PA**, Cosamanis I and Zacest R. Pharmacokinetics of hydralazine and its main metabolites in slow and fast acetylators. *Clin Pharmacol Ther* 28:769-780 (1980).
57. **Reece PA**. Quantification of prazosin in plasma by high performance liquid chromatography and fluorescence detection. *J Chromatogr* 221:188-192 (1980).
58. Schapel GJ, Beran RG, Doecke CJ, O'Reilly WJ, **Reece PA**, Rischbieth RHC, Sansom LN and Stanley PE. Pharmacokinetics of sodium valproate in epileptic patients. *Eur J Clin Pharmacol* 17:71-77 (1980).
59. **Reece PA** and Peikert M. A simple and selective HPLC method for estimating plasma quinidine levels. *J Chromatogr* 181:207-217 (1980).
60. **Reece PA**, Zacest R and Barrow G. Determination of imipramine and desipramine in plasma by high pressure liquid chromatography. *J Chromatogr* 163:310-314 (1979).
61. **Reece PA** and Cozamanis I. Injector loop sizes in high pressure liquid chromatography. *Chromatography Review* 5:14-15 (1979).
62. **Reece PA**; Stanley PE and Zacest R. Interference in the assays of hydralazine in humans by a major plasma metabolite, hydralazine pyruvic acid hydrazone. *J Pharm Sci* 67:1150-1153 (1978).
63. Armarego WLF and **Reece PA**. Purine Studies Part XX. The methylation and reduction of 2,8-dioxo-2,8-diamino- and 2-amino-8-oxo-purines and the stereochemistry of their 1,4,5,6-tetrahydroderivatives. *J C S Perk I*:1414-1424 (1976).
64. Prager R and **Reece PA**. On the alkylation of alpha-bromo ketones by trialkylboranes. *Aust J Chem* 28:1775-1783 (1975)
65. Armarego WLF and **Reece PA**. Two facile C4-N9 bond cleavages in purines and the methylation of 2,3,7,8-tetrahydro-2,8-dioxopurine. *Tet Letters*, No. 6:423-424 (1975).
66. Armarego WLF and **Reece PA**. Quinazolines. Part XXI. Synthesis of cis-2-amino-8a-carboxymethyl-3,4,4a,5,5a,7,8,8a-octahydro-quinazolines. Conversion of perhydroquinazolin-2-ones into 2-amino-3,4,4a,5,6,7,8,8a-octahydroquinazolines. *J C S Perk I*:1470-1474 (1975).
67. Armarego WLF and **Reece PA**. Quinazolines. Part XX. Synthesis and stereochemistry of N-methyl cis-perhydroquinazolin-2-ones; a new conformation for cisperhydroquinazolines. *J C S Perk I*:2313-2319 (1974).

ABSTRACTS

1. Reece PA. An update on the potential role for zanamivir in the treatment of human influenza A (H5N1) infections. Proceedings of the Influenza 2010 conference, Oxford, UK, September 21-23, 2010.
2. Reece PA and McKimm-Breschkin J. Zanamivir PK/PD: implications for the treatment of avian influenza (H5N1) infections in humans. Proceedings of EACPT, Edinburgh, July 15, 2009.
3. Tucker, SP; Nguyen, VTT; Jin, B; McConnell, DB; Watson, KG; Cameron, R; Hamilton, S; Macdonald, S; Fenton, R; Reece, PA; Wu, WY. FLUNET (R): A new approach for influenza management. *Antiviral Research* 53(3):pA65-pA65 (2002)
4. Cutler N R; Sramek J J; Seifert R D; Hourani J; Reece P A; Bockbrader H; Sedman A J; Wardle T S. Maximally tolerated dose of the muscarinic agonist CI-979 in Alzheimer's disease (AD). *Biological Psychiatry* 35 (9): 628 (1994).
5. Cutler N R; Sramek J J; Seifert R D; Hourani J; Reece P A; Bockbrader H; Sedman A J. Safety and tolerance of the muscarinic agonist CI-979. *Clinical Pharmacology & Therapeutics* 55 (2): 174 (1994).
6. De Vries T M; Siedlik P; Smithers J A; Brown R R; Reece P A; Posvar E L; Sedman A J; Koup J R; Fargue S T. Effect of multiple-dose tacrine administration on single-dose pharmacokinetics of digoxin, diazepam, and theophylline. *Pharmaceutical Research (New York)* 10 (10 SUPPL.): S333 (1993)
7. De Vries T M; O'Connor-Semmes R L; Guttendorf R J; Reece P A; Posvar E L; Sedman A J; Koup J R; Fargue S T. Effect of cimetidine and low-dose quinidine on tacrine pharmacokinetics in humans. *Pharmaceutical Research (New York)* 10 (10 SUPPLY.): S337 (1993).
8. Windsor B L; Radulovic L L; Bockbrader H N; Underwood B A; Reece P A; Sedman A J; Chang T. Application of validated GC-NPD method for quantitation of CI-979 in a clinical interaction study with Maalox TC. *Pharmaceutical Research (New York)* 10 (10 SUPPL.): S415 (1993).
9. Busch J A; Radulovic L L; Reece P A; Sedman A J; Bockbrader H N. Effect of food on the bioavailability of Neurontin 400-mg market-image Supro capsules in healthy subjects. *Pharmaceutical Research (New York)* 10 (10 SUPPL): S345 (1993)
10. Reece PA, Dawkins R, Wright S, Rajagopalan R, Sedman AJ. Dose proportionality and pharmacodynamics of intramuscular CI-977. *Clin Pharmacol Ther* 51:189 (1992).
11. Reece PA, Bockbrader H, Sedman AJ. Safety, pharmacodynamics, and pharmacokinetics of a new muscarinic agonist, CI-979. *Clin Exp Pharmacol Physiol* 21:58 (1992)
12. Olver IN, Reece PA, Morris RG, Bishop JF, Guentert TW, Hill HS, and Hillcoat BL. Phase I pharmacokinetic study of doxifluridine given by five-day stepped dose infusion. *Invest New Drugs* 7:379 (1989).

13. Reece PA, Stafford I, Freeman S, Gill PG, Davy M, Abbott RL, Olweny CLM and Denham J. Creatinine clearance as a predictor of the disposition of the anticancer drug, cisplatin in patients with cancer. Xth International Congress of Pharmacology, Sydney, August (1987).
14. Morris RG, Reece PA, Bishop JF and Olver JN. Relationship between myelosuppression and disposition of the new anticancer drug, trimetrexate. Xth International Congress of Pharmacology, Sydney, August (1987).
15. Reece PA, Stafford I, Freeman S, Gill PG, Davy M, Russell J and Khan M. Physiologically based pharmacokinetic modelling of cisplatin in patients with cancer. Clin Exp Pharmacol Physiol Suppl 11:45 (1987).
16. Reece PA et al. Interpatient differences in the elimination of anti-cancer drugs - a potentially important contributor to differences in response and toxicity. Medical and Paediatric Oncology 15:134 (1987).
17. Reece PA, Stafford I, Russell J, Khan M and Gill PG. Prediction of cisplatin disposition in patients from creatinine clearance. Relationship between unbound platinum plasma levels and the development of nephrotoxicity. Medical and Paediatric Oncology 15:122 (1987).
18. Morris RG, Reece PA, Bishop JF, Olver JN and Raghavan D. Phase I pharmacokinetic study of the methotrexate analogue, trimetrexate, in patients with advanced cancer. Medical and Paediatric Oncology 15:124 (1987).
19. Olver JN, Bishop JF, Raghavan D, Reece PA and Morris RG. Phase I study of trimetrexate (TMTX) as a five day continuous infusion. Medical and Paediatric Oncology 15:151 (1987).
20. Reece PA, Stafford I, Davy M and Freeman S. Disposition of unchanged cisplatin in patients with ovarian cancer. Proc Amer Assoc Cancer Res 28:193 (1987).
21. Stafford I, Reece PA, Russell J and Gill PG. Reduced ability to clear unbound platinum, with repeated courses of cisplatin to patients. Clin Exp Pharmacol Physiol Suppl 10:81 (1987).
22. Morris RG, Reece PA, Dale BM, Kotasek D, Gee D and Sage RE. Effect of the dietary amino-acid L-leucine on oral melphalan absorption. Clin Exp Pharmacol Physiol Suppl 10:90 (1987).
23. Reece PA, Stafford I, Russell J and Gill PG. Ultrafilterable platinum disposition in patients following cisplatin infusion - What is the correct model? Abstract 1137, Proc Amer Assoc Cancer Res 27:287 (1986).
24. Morris RG, Reece PA, Bishop J, Olver J and Raghavan D. Disposition of a new methotrexate analogue, trimetrexate, given by five day infusion to patients. Abstract of paper presented at the Third World Conference on Clinical Pharmacology and Therapeutics, Stockholm, Sweden, July 1986.
25. Powis G, Reece PA, Ingle JN and Ahmann DL. Cyclophosphamide pharmacokinetics in obese cancer patients. Acta Pharm Tox 59(Suppl V):296 (1986).
26. Reece PA, Stafford I, Russell J and Gill PG. Cisplatin pharmacokinetics - nonlinear renal clearance and prolonged plasma levels in patients. Med Pediatr Oncol 13:147 (1985).

27. Morris RG, Reece PA, Kotasek P, Dale BM and Sage RE. Food reduces oral melphalan absorption. *Clin Exp Pharmacol Physiol Supp* 9:100 (1985).
28. Reece PA, Stafford I, Russell J and Gill PG. Nonlinear renal clearance and prolonged plasma levels of unbound platinum in patients administered cisplatin. *Clin Exp Pharmacol Physiol Supp* 9:42 (1985).
29. Schapel GJ, Robinson MK, Barrell ML, Reece PA, and Texler KC. Phenytoin (DPH) dosage in severe pre-eclamptic toxemia (PET). *Clin Exp Pharmacol Physiol Suppl* 9:54 55 (1985).
30. Stafford I, Reece PA, Prager RH, Walker GJ and Zacest R. The synthesis formulation and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone. *Clin Exp Pharmacol Physiol Suppl* 9:97 98 (1985).
31. Reece PA, Stafford I, Russell J and Gill PG. Cisplatin pretreatment reduces unbound platinum renal clearance in patients. Abstract 1384, *Proc Amer Assoc Cancer Res* 26:351 (1985).
32. Bochner F, Imhoff DM, Reece PA, Dimitriadis E and Ward AD. Direct measurement of salicyl phenolic glucuronide in human urine. Abstract of a meeting of the II World Conference on Clinical Pharmacology and Therapeutics, Washington, U.S.A., August 1983.
33. Reece PA, Cozamanis I and Zacest R. Endralazine - a vasodilator with high systemic bioavailability. Abstract of a meeting of the II World Conference on Clinical Pharmacology and Therapeutics, Washington, U.S.A., August 1983.
34. Reece PA and Powis G. Technique for determining extracellular fluid drug levels - application to cisplatin pharmacokinetic studies. *Clin Exp Pharmacol Physiol* 10(6), (1983).
35. Reece PA, Cozamanis I and Zacest R. Simultaneous pharmacokinetic and pharmacodynamic study of endralazine in healthy volunteers. I. Pharmacokinetics *Clin Exp Pharmacol Physiol* 9:477 (1982).
36. Zacest R, Cozamanis I and Reece PA. Simultaneous pharmacokinetic and pharmacodynamic study of endralazine in healthy volunteers. II. Pharmacodynamics. *Clin Exp Pharmacol Physiol* 9:477 478 (1982).
37. Reece PA, Cozamanis I and Zacest R. Specific assay and initial pharmacokinetics of a new vasodilator antihypertensive, endralazine. *Clin Exper Pharmacol Physiol* 8:602 (1981).
38. Reece PA, Cozamanis I and Zacest R. HPLC-fluorescence assay for the antihypertensive drug endralazine and two of its metabolites in human plasma. Abstract of a meeting of the Royal Australian Chemical Institute, Canberra, Australia, August 1981.
39. Reece PA, Cozamanis I and Zacest R. New insights into hydralazine plasma clearance following intravenous infusion to human volunteers. *Clin Pharmacol Ther* 27:280 (1980).

40. Cozamanis I, Reece PA and Zacest R. Fate of oral hydralazine in slow and fast acetylators. Clin Exper Pharmacol Physiol 7:678-679 (1980).
41. Reece PA and Zacest R. Towards specific methods for hydrallazine assay. Clin Exp Pharmacol Physiol 6:207 208 (1979).
42. Lo M, Reece PA and Riegelman S. HPLC determination of propranolol and metabolites in plasma and urine. Clin Exp Pharmacol Physiol 6:698 699 (1979).
43. Lo M, Reece PA and Riegelman S. Determination of propranolol and its metabolites in plasma and urine by HPLC. APha Academy of Pharmaceutical Sciences 25th National Meeting, Abstracts, 8/2, 87 (1978).
44. Reece PA and Zacest R. Significance of "Apparent Hydrallazine" levels in plasma of man. Clin Exp Pharmacol Physiol 5:248 (1978).
45. Zacest R and Reece PA. Hydrallazine metabolism in renal failure. Aust NZ J Med 7:551 (1977).

PATENTS

1. WO/2001/019822, ANTIVIRAL AGENTS, 22.03.2001, A61K 31/4245, PCT/AU2000/001126, BIOTA SCIENTIFIC MANAGEMENT PTY. LTD.; published in March 2001.
2. WO/1998/021243, METHOD AND NOVEL COMPOUNDS FOR USE THEREIN, 22.05.1998, C08B 37/02, PCT/AU1997/000771, BIOTA SCIENTIFIC MANAGEMENT PTY. LTD.; granted in Australia and New Zealand and published in May 1998.
3. WO/1997/032214, METHOD OF DETECTION OF INFLUENZA VIRUS AND COMPOUNDS FOR USE THEREIN, 04.09.1997, C07D 309/28, PCT/AU1997/000109, BIOTA SCIENTIFIC MANAGEMENT PTY. LTD.; granted in Australia and New Zealand and published in September 1997.

MOST RECENT PRESENTATION

An update on the potential role for zanamivir in the treatment of human influenza A (H5N1) infections at Influenza 2010, St Hilda's College, Oxford, UK, September 21-23, 2010.